483 related articles for article (PubMed ID: 28314744)
1. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
Ravani P; Bonanni A; Ghiggeri GM
BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
[TBL] [Abstract][Full Text] [Related]
2. Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol.
Lugani F; Angeletti A; Ravani P; Vivarelli M; Colucci M; Caridi G; Verrina E; Emma F; Ghiggeri GM
BMJ Open; 2021 Nov; 11(11):e052450. PubMed ID: 34845071
[TBL] [Abstract][Full Text] [Related]
3. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
[TBL] [Abstract][Full Text] [Related]
5. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
[TBL] [Abstract][Full Text] [Related]
6. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.
Ravani P; Magnasco A; Edefonti A; Murer L; Rossi R; Ghio L; Benetti E; Scozzola F; Pasini A; Dallera N; Sica F; Belingheri M; Scolari F; Ghiggeri GM
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1308-15. PubMed ID: 21566104
[TBL] [Abstract][Full Text] [Related]
7. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
Bonanni A; Calatroni M; D'Alessandro M; Signa S; Bertelli E; Cioni M; Di Marco E; Biassoni R; Caridi G; Ingrasciotta G; Bertelli R; Di Donato A; Bruschi M; Canepa A; Piaggio G; Ravani P; Ghiggeri GM
Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
[TBL] [Abstract][Full Text] [Related]
9. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.
Ravani P; Rossi R; Bonanni A; Quinn RR; Sica F; Bodria M; Pasini A; Montini G; Edefonti A; Belingheri M; De Giovanni D; Barbano G; Degl'Innocenti L; Scolari F; Murer L; Reiser J; Fornoni A; Ghiggeri GM
J Am Soc Nephrol; 2015 Sep; 26(9):2259-66. PubMed ID: 25592855
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
[TBL] [Abstract][Full Text] [Related]
14. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome.
Colucci M; Angeletti A; Zotta F; Carsetti R; Lugani F; Ravà L; Ravani P; Emma F; Ghiggeri GM; Vivarelli M
Kidney Int; 2023 Sep; 104(3):577-586. PubMed ID: 37385541
[TBL] [Abstract][Full Text] [Related]
15. Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial.
Ravani P; Pisani I; Bodria M; Caridi G; Degl'Innocenti ML; Ghiggeri GM
Pediatr Nephrol; 2020 Jun; 35(6):997-1003. PubMed ID: 31993781
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
[TBL] [Abstract][Full Text] [Related]
18. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
19. Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome.
Bernard J; Bruel A; Allain-Launay E; Dantal J; Roussey G
Pediatr Transplant; 2018 Jun; 22(4):e13175. PubMed ID: 29569812
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Rituximab in Children With Steroid- and Cyclosporine-resistant and Steroid- and Cyclosporine-dependent Nephrotic Syndrome.
Hoseini R; Sabzian K; Otukesh H; Zafaranloo N; Panahi P; Rahimzadeh N; Nakhaie S; Akhavan Sepehi M
Iran J Kidney Dis; 2018 Jan; 12(1):27-32. PubMed ID: 29421774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
